Home
News
- 1 CEL-SCI Corporation (NYSE AMERICAN: CVM) stock lost 23.43% of its trading price on July 18.
- 2 In the 52-week time frame, CVM stock’s lowest trading price was $1.86, and its highest was $5.42.
CEL-SCI Corporation (NYSE AMERICAN: CVM) stock lost 23.43% of its trading price on July 18. It opened trading at $2.21, dipped to $2.17, hit a high of $2.21, and closed trading at $2.20 with an intraday trading volume of 32.089K.
In the 52-week time frame, CVM stock’s lowest trading price was $1.86, and its highest was $5.42. The annual price target of CEL-SCI Corporation stock is $10, which is around 356.62% higher than the current trading price.
CEL-SCI Corporation’s market capitalization is $98.003 Million, and its average trading volume is 591.207K. CVM stock declined 0.46% in the pre-market trading session.
Over the past 6 months, CVM stock consolidated between the range of $2 and $3. It is trading below the 200 and 50-day EMAs, signaling a further decline in the upcoming sessions.
CVM Stock – What the Chart Shows
CEL-SCI Corporation tried multiple times to break $3 but faced rejection, indicating that sellers are more active than buyers. The immediate support of CVM stock is $2, and if it fails to sustain the price, it might slip to $1.50.
The immediate resistance of CVM stock is $3. If it beats the immediate resistance, it might hit $3.50. CVM stock slipped over 5.19% in the monthly time frame, and in a year, prices are down over 44.84%. In the July 18 trading session, sellers were dominant and were trying hard to drag the prices toward the immediate support level.
TradingView shows that 43.042 Million CVM shares are free-floating, and the remaining 1.708 million shares are closely held by the company’s financial backers or the board of directors.
The company’s total assets in the short-term are $25.44 Million, and its liabilities are $4.66 Million. In the long-term, the total assets of CEL-SCI Corporation are $25.09 Million, and liabilities are $13.07 Million.
CEL-SCI Corporation Earnings & Revenue
In Q1 2023, CEL-SCI Corporation’s revenue was nil, and its net income was -$7.85 Million, gross profit was -$993.62k, operating income was -$7.65, and pretax income was -$7.85.
Similarly, in Q2, revenue of the company was nil, but its net income was -$8.34 Million, including -$989.91k of gross profit, -$8.18 Million operating income, and -$8.34 Million pretax income.
On July 17, CEL-SCI Corporation announced that it plans to offer to sell shares of its common stock in an underwritten public offering. The company hopes to grant the underwriter a 45-day option to buy up to an additional 15% of the shares of common stock marketed in this offering to cover over-allotments.
CEL-SCI Corp is a biotechnology-focused company engaged in researching and developing investigational immunotherapy products to treat cancer and infectious diseases.
Disclaimer
The views and opinions stated by the author, or any people named in this article, are for informational ideas only and do not establish financial, investment, or other advice. Investing in or trading crypto assets comes with a risk of financial loss.
Andrew is a blockchain developer who developed his interest in cryptocurrencies while pursuing his post-graduation major in blockchain development. He is a keen observer of details and shares his passion for writing, along with coding. His backend knowledge about blockchain helps him give a unique perspective to his writing skills, and a reliable craft at explaining the concepts such as blockchain programming, languages and token minting. He also frequently shares technical details and performance indicators of ICOs and IDOs.
